AMP.L Share News (AMP)

WINNERS & LOSERS SUMMARY: Dixons And Next Up But Morrisons Sinks

Amphion Innovations' DataTern Gets Favourable Patent Dispute Ruling

WINNERS & LOSERS SUMMARY: M&A Speculation And Upgrade Boost Morrisons

Amphion Innovations Sees "Dramatic Rise" In Value On Motif Bio Float

Amphion Innovations Confident After Motif IPO, 2014 Asset Value Fall

LONDON MIDDAY BRIEFING: Vodafone In Asset Swap Talks With Liberty

WINNERS & LOSERS: Halfords Rides Higher As Sales Hit GBP1 Billion

Amphion Innovations Raises GBP1.5 Million In Discounted Issue (ALLISS)

LONDON MORNING BRIEFING: Next And Burberry Shares In Fashion

Amphion Shares Up As Motif Bio Gets US FDA Approval For Iclaprim Trial

Amphion Innovations Gets GBP580,842 From Exercised Warrants (ALLISS)

Motif Bio makes AIM debut, seeks approval for Iclaprim treatment

Clinical stage biopharmaceutical group Motif Bio began trading on AIM on Thursday, after raising £2.8m in its initial public offering. The group, whose 44.09% of issued equity is owned by Amphion, placed shares at 20p each, said it had 64,238,442 ordinary shares in issue and a market capitalisation

BCA Marketplace, Marshall Motor And Motif Bio Begin Trading (ALLIPO)

Amphion Issues 1.3 Million Shares At GBP0.0266 To YA Global Master (ALLISS)

LONDON MIDDAY BRIEFING: TSB Banking To Go The Way Of Abbey National